Practice
Featured experience
Emerson $7.2 billion acquisition of remaining outstanding shares of AspenTech
We are advising Emerson on its acquisition
Intra-Cellular Therapies $14.6 billion acquisition by Johnson & Johnson
We are advising Intra-Cellular Therapies on the transaction
GSK up to $1.15 billion acquisition of IDRx
We are advising GSK on the transaction
Royalty Pharma $1.1 billion acquisition of its external manager and $3 billion share repurchase
We are advising Royalty Pharma on the transaction
Truist $15.5 billion sale of remaining stake in Truist Insurance to investor group
We are advising Truist on the transaction
HireRight $1.65 billion acquisition by General Atlantic and Stone Point Capital
We are advising the special committee of HireRight on the transaction
Gilead Sciences $4.3 billion acquisition of CymaBay Therapeutics
We are advising Gilead Sciences on the acquisition
Owens Corning $3.9 billion acquisition of Masonite International
We are advising Owens Corning on the acquisition
MSCI acquisition of Foxberry
We are advising MSCI on the acquisition
Kemmerer family sale of Jackson Hole Mountain Resort
We advised the Kemmerer family on the sale
Novo Nordisk acquisition of certain Catalent sites from Novo Holdings
We are advising Novo Nordisk on the acquisition
Truist sale of Sterling Capital Management to Guardian Capital
We are advising Truist on the transaction
Camin Cargo Control sale to Macquarie Group
We advised Camin Cargo Control and Metalmark Capital on the transaction
Ankura Consulting Group acquisition of Lumeri
We are advising Ankura on the acquisition